MIM
IBIO icon

MetLife Investment Management’s iBio IBIO Stock Holding History

MetLife Investment Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-166
Closed -$88.2K – 2523
2021
Q3 		$88.2K Buy
+166
New +$103K ﹤0.01% 2486
2021
Q2 		– Sell
-21
Closed -$16.5K – 2456
2021
Q1 		$16.5K Buy
+21
New +$18.3K ﹤0.01% 2307

Other funds holding IBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MetLife Investment Management's IBIO Position: Q4 2021 in Review

MetLife Investment Management sold out of iBio (IBIO) in Q4 2021, closing a stake of 166 shares — an estimated $88.2K sold.

MetLife Investment Management first reported a position in IBIO in Q1 2021 and held it in 2 quarters. The position peaked at $88.2K in Q3 2021. 77 funds tracked by Wall St. Rank hold IBIO as of Q4 2021.

  • MetLife Investment Management reported no remaining iBio position as of Q4 2021 after selling out during the quarter.
  • MetLife Investment Management sold 166 iBio shares in Q4 2021, an estimated $88.2K.
  • MetLife Investment Management first reported a position in iBio in Q1 2021 and held it in 2 quarters.
  • MetLife Investment Management's iBio position peaked at $88.2K in Q3 2021.
  • 77 funds tracked by Wall St. Rank held iBio as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.